Search Result

Results for "

radiotherapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Akt (3) Apoptosis (3) Aurora Kinase (1) Autophagy (1) BCRP (3) Biochemical Assay Reagents (5) Caspase (2) Checkpoint Kinase (Chk) (1) Dihydropyrimidine Dehydrogenase (DPD) (2) DNA-PK (7) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) EGFR (2) ERK (1) FAP (1) FGFR (1) FOXO (1) Influenza Virus (1) Interleukin Related (3) Isotope-Labeled Compounds (3) MMP (3) Necroptosis (1) NEKs (1) Neurokinin Receptor (1) NF-κB (1) NOD-like Receptor (NLR) (2) p38 MAPK (1) PD-1/PD-L1 (1) PERK (1) Phosphodiesterase (PDE) (1) PI3K (3) Prostaglandin Receptor (1) PROTACs (1) PSMA (2) Pyroptosis (2) Radionuclide-Drug Conjugates (RDCs) (3) Raf (1) Reactive Oxygen Species (ROS) (4) Reference Standards (5) RIP kinase (1) SGK (3) TNF Receptor (3) Toll-like Receptor (TLR) (1) YTHDF (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (5) Endocrinology (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (9)

By Targets:

5-HT Receptor (7)

Akt (3)

Apoptosis (3)

Aurora Kinase (1)

Autophagy (1)

BCRP (3)

Biochemical Assay Reagents (5)

Caspase (2)

Checkpoint Kinase (Chk) (1)

Dihydropyrimidine Dehydrogenase (DPD) (2)

DNA-PK (7)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Drug Intermediate (1)

Drug Isomer (1)

EGFR (2)

ERK (1)

FAP (1)

FGFR (1)

FOXO (1)

Influenza Virus (1)

Interleukin Related (3)

Isotope-Labeled Compounds (3)

MMP (3)

Necroptosis (1)

NEKs (1)

Neurokinin Receptor (1)

NF-κB (1)

NOD-like Receptor (NLR) (2)

p38 MAPK (1)

PD-1/PD-L1 (1)

PERK (1)

Phosphodiesterase (PDE) (1)

PI3K (3)

Prostaglandin Receptor (1)

PROTACs (1)

PSMA (2)

Pyroptosis (2)

Radionuclide-Drug Conjugates (RDCs) (3)

Raf (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (5)

RIP kinase (1)

SGK (3)

TNF Receptor (3)

Toll-like Receptor (TLR) (1)

YTHDF (1)

By Research Areas:

Cancer (39)

Cardiovascular Disease (5)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101570

Nedisertib Maximum Cited Publications 27 Publications Verification Peposertib; M3814	DNA-PK BCRP	Cancer
Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

HY-N0305

5-Aminolevulinic acid hydrochloride 15+ Cited Publications 5-ALA hydrochloride; δ-Aminolevulinic acid hydrochloride; 5-Amino-4-oxopentanoic acid hydrochloride	Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) hydrochloride is an orally active heme precursor. 5-Aminolevulinic acid hydrochloride promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid hydrochloride enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid hydrochloride selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid hydrochloride can be applied to the research of septic shock, melanoma, and cancer radiotherapy .

HY-B0002B

Ondansetron 5+ Cited Publications GR 38032; SN 307	5-HT Receptor	Neurological Disease
Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-164388

Z-VAD 15+ Cited Publications	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .

HY-W000450

5-Aminolevulinic acid 15+ Cited Publications 5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid	Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) is an orally active heme precursor. 5-Aminolevulinic acid promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid can be applied to the research of septic shock, melanoma, and cancer radiotherapy .

HY-15193

EMD638683 15+ Cited Publications	SGK NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Cancer
EMD638683 is an orally active SGK1 inhibitor with an IC₅₀ of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer .

HY-W020780

mPEG5000-Mal mPEG5000-Maleimide	Biochemical Assay Reagents	Cancer
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses .

HY-B0002

Ondansetron hydrochloride 5+ Cited Publications GR 38032 hydrochloride; SN 307 hydrochloride	5-HT Receptor	Neurological Disease
Ondansetron (GR 38032; SN 307) hydrochloride is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron hydrochloride exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-154919

DC-Y13-27 4 Publications Verification	YTHDF FOXO MMP Pyroptosis Interleukin Related	Endocrinology Cancer
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .

HY-B0002A

Ondansetron hydrochloride dihydrate 5+ Cited Publications GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate	5-HT Receptor	Neurological Disease
Ondansetron (GR 38032; SN 307) hydrochloride dehydrate is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron hydrochloride dehydrate exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride dehydrate can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-10251

BMS-599626 3 Publications Verification AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-111940

LUT014	Raf p38 MAPK ERK	Inflammation/Immunology
LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .

HY-17469

Gimeracil 3 Publications Verification Gimestat	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent Nek1 inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-119307

Apratastat 4 Publications Verification TMI-005	MMP TNF Receptor	Cancer
Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC) . Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19416

AEOL-10150 pentachloride 1 Publications Verification	Reactive Oxygen Species (ROS) NF-κB	Inflammation/Immunology Cancer
AEOL-10150 pentachloride is a metalloporphyrin-catalyzed antioxidant and a superoxide dismutase mimetic. AEOL-10150 pentachloride scavenges ROS and RNS, and modulates the NF-κB signaling pathway. AEOL-10150 pentachloride has potent antioxidant and anti-inflammatory activities. AEOL-10150 pentachloride effectively mitigates tissue damage caused by radiation and chemical agents such as CEES (HY-W199190). AEOL-10150 pentachloride synergizes with radiotherapy to exert anticancer effects on prostate tumors .

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-175370

PROTAC RIPK1 Degrader-1	PROTACs RIP kinase	Cancer
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .

HY-122168

AAT-008	Prostaglandin Receptor	Inflammation/Immunology Cancer
AAT-008 is a potent, selective, and orally active prostaglandin EP4 receptor antagonist with K_is of 0.97 and 6.1 nM for recombinant human EP4 and recombinant rat EP4, respectively. AAT-008 exerts tumor growth delay in mice bearing CT26WT colon tumors when combined with radiotherapy. AAT-008 can be used for the study of acute and chronic inflammatory pain and cancer .

HY-15193B

EMD638683 (S-Form)	SGK Drug Isomer	Cardiovascular Disease Cancer
EMD638683 (S-Form) (Compound 1a), the S-enantiomer of EMD638683 (HY-15193), is a SGK1 inhibitor with an IC₅₀ value > 300 nM. EMD638683 is an orally active SGK1 inhibitor with an IC₅₀ of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer .

HY-134181A

Tremella polysaccharide, MW<1000000, cosmetic grade	Biochemical Assay Reagents	Inflammation/Immunology
Tremella polysaccharide, MW<1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-123733A

MIP-1095 TFA RPS-001 TFA	PSMA	Cancer
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( ¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice .

HY-B0002BS

Ondansetron-d5 GR 38032-d₅; SN 307-d₅	5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Ondansetron-d₅ is the deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-W010023

2-Amino-3-bromo-5-fluoropyridine 3-Bromo-5-fluoro-2-pyridinamine	Drug Intermediate	Others
2-Amino-3-bromo-5-fluoropyridine (3-Bromo-5-fluoro-2-pyridinamine) is a drug intermediate that can be used for the synthesis fluorinated pyridines .

HY-177551

CHK1-IN-14	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-14 is a free base form of CHK1 inhibitor. CHK1-IN-14 can be used in research on resistance to chemotherapy and radiotherapy .

HY-P3566

(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)	Biochemical Assay Reagents	Others
(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the reaction product with gadolinium tetraazacyclododecanetriacetate derivative. (D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) involves in preparation of tetraazacyclododecane macrocycle metal complexes for production of conjugates with biomolecules and for use as NMR contrast agents, radiodiagnostic agents and for radioresearch .

HY-101570G

Nedisertib Peposertib; M3814	DNA-PK BCRP	Cancer
Nedisertib (GMP) (Peposertib (GMP)) is Nedisertib (HY-101570) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Nedisertib is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

HY-15193R

EMD638683 (Standard)	Reference Standards SGK NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Cancer
EMD638683 (Standard) is the analytical standard of EMD638683. This product is intended for research and analytical applications. EMD638683 is an orally effective SGK1 inhibitor with an IC₅₀ of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer.

HY-134181

Tremella polysaccharide, MW>1000000, cosmetic grade	Biochemical Assay Reagents	Inflammation/Immunology
Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-172137

FAPI-FUSCC-07	FAP	Cancer
FAPI-FUSCC-07 is a targeted probe for fibroblast activation protein (FAP), exhibiting high affinity binding to FAP for applications in molecular imaging, tumor diagnosis, and radiotherapy .

HY-121496

3M-011	Toll-like Receptor (TLR) Influenza Virus	Infection Inflammation/Immunology Cancer
3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action .

HY-163683

EB-PSMA-617	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .

HY-114923

SU-11752	DNA-PK PI3K	Cancer
SU-11752 is an inhibitor for DNA-dependent protein kinase (DNA-PK) with an IC₅₀ of 0.13 μM. SU-11752 inhibits PI3K p110γ kinase with IC₅₀ of 1.1 μM. SU-11752 binds competitively for ATP-site in DNA-PK, results in inhibition of intracellular DNA double-strand break repair and increases the sensitivity of cells to radiotherapy .

HY-171561

DOTAM-Maleimide triTFA	Biochemical Assay Reagents	Others
DOTAM-Maleimide triTFA is a bifunctional chelator, combining the DOTAM structure with a maleimide group for efficient thiol coupling. DOTAM-Maleimide triTFA forms stable complexes with radiometals, promising for applications in molecular imaging and radiotherapy .

HY-144036

DNA-PK-IN-3	DNA-PK	Cancer
DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4) .

HY-175779

TDP1-IN-4	Phosphodiesterase (PDE)	Cancer
TDP1-IN-4 (Compound 33) is a Tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC₅₀ of 0.90  μM. TDP1-IN-4 has a strong synergistic effect with Camptothecin (HY-16560) in SK-Mel-2 cells, but not in cancer cells (A549, HCT-116 and MCF-7 cells) and non-cancerous Ges-1 cells. TDP1-IN-4 can be used for cancer chemotherapy and radiotherapy research .

HY-144038

DNA-PK-IN-5	DNA-PK	Cancer
DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2) .

HY-144039

DNA-PK-IN-6	DNA-PK	Cancer
DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6) .

HY-17469R

Gimeracil (Standard) Gimestat (Standard)	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Reference Standards	Cancer
Gimeracil (Standard) is the analytical standard of Gimeracil. This product is intended for research and analytical applications. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-10180A

MLN8054 sodium	Aurora Kinase	Cancer
MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .

HY-119307R

Apratastat (Standard) TMI-005 (Standard)	MMP TNF Receptor Reference Standards	Cancer
Apratastat (Standard) is the analytical standard of Apratastat. This product is intended for research and analytical applications. Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC) . Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116604

RLX PD 139530	PI3K Akt	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .

HY-B0002BS1

Ondansetron-d3 GR 38032-d₃; SN 307-d₃	5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Ondansetron-d₃ is the deuterium labeled Ondansetron (HY-B0002B ). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-B0002BR

Ondansetron (Standard) GR 38032 (Standard); SN 307 (Standard)	Reference Standards 5-HT Receptor	Neurological Disease Cancer
Ondansetron (Standard) is the analytical standard of Ondansetron (HY-B0002B). This product is intended for research and analytical applications. Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-B0002BS2

Ondansetron-13C,d3 GR 38032-¹³C,d₃; SN 307-¹³C,d₃	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Ondansetron- ¹³C,d₃ is the ¹³C- and deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-116604A

RLX hydrochloride PD 139530 hydrochloride	PI3K Akt	Cancer
RLX (PD 139530) hydrochloride is the hydrochloride of RLX (HY-116604). RLX is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .

HY-106185

BMS-188797	Drug Derivative	Cancer
BMS-188797 is a novel Taxane analog. BMS-188797 enhances the efficacy of radiotherapy against lung cancer .

HY-181005

FGFR-IN-25	FGFR Akt PERK Reactive Oxygen Species (ROS) Caspase Pyroptosis PD-1/PD-L1	Neurological Disease Cancer
FGFR-IN-25 (Compound 19E) is a FGFR inhibitor (IC₅₀s: 1.30 nM and 0.85 nM for FGFR1 and FGFR2, respectively) and radiosensitizer. FGFR-IN-25 effectively reduces the phosphorylation of FGFR1 and its key downstream effectors, pAKT and pERK. FGFR-IN-25 exerts broad-spectrum antitumor activity against gastric cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, triple-negative breast cancer, and glioblastoma. FGFR-IN-25, when combined with radiotherapy, synergistically activates the ROS-Caspase-3-GSDME axis, downregulates PD-L1 expression, and induces immunogenic cell death (ICD). FGFR-IN-25 combined with radiotherapy improves the antitumor efficacy .

HY-153709

Zalsenertant tetraxetan IPN-01087	Neurokinin Receptor	Cancer
Zalsenertant tetraxetan (IPN-01087) is a DOTA-conjugated antagonist of the neurohypophyseal hormone receptor subtype 1 (NTSR1). Zalsenertant tetraxetan is labeled with the radioactive isotope Lu-177 (177Lu), which can be used for molecular imaging to identify potential responders. Zalsenertant tetraxetan can be used in the radiotherapy research of solid tumors .

HY-101570R

Nedisertib (Standard) Peposertib (Standard); M3814 (Standard)	DNA-PK Reference Standards BCRP	Cancer
Nedisertib (Standard) is the analytical standard of Nedisertib (HY-101570). This product is intended for research and analytical applications. Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

Cat. No.	Product Name

HY-L179

Radiosensitizer Library

41 compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

HY-L171

Anti-Hematopathy Compound Library

4,172 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L135

Cancer Stem Cells Compound Library

3,355 compounds

With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.

Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.

MCE supplies a unique collection of 3,355 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

HY-L074

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-W020780

mPEG5000-Mal

mPEG5000-Maleimide

Biochemical Assay Reagents

mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses .

HY-134181A

Tremella polysaccharide, MW<1000000, cosmetic grade	Biochemical Assay Reagents
Tremella polysaccharide, MW<1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-W010023

2-Amino-3-bromo-5-fluoropyridine 3-Bromo-5-fluoro-2-pyridinamine	Biochemical Assay Reagents
2-Amino-3-bromo-5-fluoropyridine (3-Bromo-5-fluoro-2-pyridinamine) is a drug intermediate that can be used for the synthesis fluorinated pyridines .

HY-134181

Tremella polysaccharide, MW>1000000, cosmetic grade	Biochemical Assay Reagents
Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

Cat. No.	Product Name	Target	Research Area

HY-164388

Z-VAD 15+ Cited Publications	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .

HY-P3566

(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)	Biochemical Assay Reagents	Others
(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the reaction product with gadolinium tetraazacyclododecanetriacetate derivative. (D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) involves in preparation of tetraazacyclododecane macrocycle metal complexes for production of conjugates with biomolecules and for use as NMR contrast agents, radiodiagnostic agents and for radioresearch .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

HY-P992340

CTB006	Radionuclide-Drug Conjugates (RDCs) TNF Receptor	Cancer
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. ¹⁷⁷Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while ⁸⁹Zr- or ¹⁷⁷Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0305

5-Aminolevulinic acid hydrochloride 15+ Cited Publications 5-ALA hydrochloride; δ-Aminolevulinic acid hydrochloride; 5-Amino-4-oxopentanoic acid hydrochloride	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Cancer	Reactive Oxygen Species (ROS)
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) hydrochloride is an orally active heme precursor. 5-Aminolevulinic acid hydrochloride promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid hydrochloride enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid hydrochloride selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid hydrochloride can be applied to the research of septic shock, melanoma, and cancer radiotherapy .

HY-W000450

5-Aminolevulinic acid 15+ Cited Publications 5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid	Cardiovascular Disease Structural Classification Classification of Application Fields Amino acids Endogenous metabolite Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS)
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) is an orally active heme precursor. 5-Aminolevulinic acid promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid can be applied to the research of septic shock, melanoma, and cancer radiotherapy .

Cat. No.	Product Name	Chemical Structure

HY-B0002BS

Ondansetron-d5

Ondansetron-d₅ is the deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-B0002BS1

Ondansetron-d3

Ondansetron-d₃ is the deuterium labeled Ondansetron (HY-B0002B ). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

HY-B0002BS2

Ondansetron-13C,d3

Ondansetron- ¹³C,d₃ is the ¹³C- and deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist with an IC₅₀ value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101570G

Nedisertib Peposertib; M3814	DNA-PK BCRP	Cancer
Nedisertib (GMP) (Peposertib (GMP)) is Nedisertib (HY-101570) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Nedisertib is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

radiotherapy

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products